Anna M. Schläfli

Anna M. Schläfli

Auto-generated profile, based on publicly available information

Anna M. Schläfli

Institute of Tissue Medicine and Pathology, University of Bern

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2021 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Open access
ITIgor Tokarchuk
Igor Tokarchuk
FJFélice A. Janser
Félice A. Janser
ASAnna M. Schläfli
Anna M. Schläfli
MPMarta Pinto
Marta Pinto
Magali HumbertMagali Humbert
Magali Humbert
Mario P. TschanMario P. Tschan
Mario P. Tschan
Chaperone Mediated Autophagy (CMA) is a selective autophagy pathway deregulated in many cancers. In this study, we were aiming at understanding the importance of CMA in breast cancer. To this end, we examined the expression of the CMA markers HSP8 and LAMP2A in different breast cancer cell lines and found a wide range of LAMP2A expression levels across the cell lines analyzed. Next, we applied a specific immunohistochemical staining protocol to a tissue microarray derived from a cohort of 365 breast cancer patients. Therefore, we were able to find a correlation of high LAMP2A but not HSPA8 (HSC70) with worse disease free survival in patients with HER2 negative tumors (p = 0.026) which was independent prognostic parameter from pT category, pN category and grading in a multivariate model (HR = 1.889; 95% CI = 1.039–3.421; p = 0.037). In line, low LAMP2A levels decrease proliferation of the breast cancer cell lines T47D and MCF-7 in vitro. Our data suggest that LAMP2A supports a more severe breast cancer cell phenotype.

30 November 2021 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
TLTereza Losmanová
Tereza Losmanová
FJFélice Ariane Janser
Félice Ariane Janser
Magali HumbertMagali Humbert
Magali Humbert
ITIgor Tokarchuk
Igor Tokarchuk
ASAnna M. Schläfli
Anna M. Schläfli
SBSabina Berezowska
Sabina Berezowska
[This corrects the article DOI: 10.1155/2020/8506572.].

21 January 2025 in European Journal of Histochemistry
Verified
Journal Article
Open access
YMYasmeen H. Mady
Yasmeen H. Mady
CKCarmen G. Kalbermatter
Carmen G. Kalbermatter
MKMaarij Khan
Maarij Khan
ASAnna M. Schläfli
Anna M. Schläfli
RMRina Mehmeti
Rina Mehmeti
Mario P. TschanMario P. Tschan
Mario P. Tschan
Accurate differentiation of homologous proteins that share high sequence identity remains a significant challenge in biomedical research, as conventional antibodies often lack sufficient specificity, leading to potential misinterpretations. This issue is particularly evident in the study of hexokinases, a family of isoenzymes that catalyze the first step of glycolysis by phosphorylating glucose. Beyond their canonical metabolic roles, hexokinases play critical non-glycolytic functions, especially in cancer biology. However, their unique tissue distributions and context-dependent roles are often obscured by the overlapping specificities of commercially available antibodies, which can produce misleading results. In this study, we rigorously evaluated a panel of antibodies targeting hexokinase isoenzyme 3 (HK3), highlighting the widespread issue of cross-reactivity and insufficient validation. Through this process, we identified and validated a highly specific antibody for HK3, demonstrating its reliability in western blot and immunohistochemistry applications. Using this validated tool, we reveal the distinct localization of HK3 in myeloid cell populations, providing new insights into its potential functional roles in these cells. This work addresses a critical gap in antibody specificity and establishes HK3 as a uniquely expressed gene in myeloid and immune cells and is absent in other cell types under basal conditions. Providing a foundation for future investigations into its context-dependent functions.